Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 3;7(9):e2434622.
doi: 10.1001/jamanetworkopen.2024.34622.

Incidence, Prevalence, and Survival of Prostate Cancer in the UK

Eng Hooi Tan  1 , Edward Burn  1 , Nicola L Barclay  1 , Antonella Delmestri  1 , Wai Yi Man  1 , Asieh Golozar  2   3 , Àlvar Roselló Serrano  4 , Talita Duarte-Salles  5   6 , Philip Cornford  7   8 , Daniel Prieto Alhambra  1   6 , Danielle Newby  1 ; OPTIMA Consortium
Affiliations

Incidence, Prevalence, and Survival of Prostate Cancer in the UK

Eng Hooi Tan et al. JAMA Netw Open. .

Abstract

Importance: Incidence, prevalence, and survival are pertinent measures to inform the management and provision of prostate cancer care.

Objective: To calculate the incidence, prevalence, and survival rates for prostate cancer in the UK from 2000 to 2021.

Design, setting, and participants: This population-based cohort study uses routinely collected primary care data from the UK. Male patients aged 18 years or older with at least 1 year of history registered in Clinical Practice Research Datalink (CPRD) GOLD or Aurum were included. Data were analyzed from January 2023 to March 2024.

Main outcomes and measures: Prostate cancer incidence rates (IR), period prevalence (PP), and 1-, 5-, and 10-year survival after diagnosis between 2000 and 2021, stratified by age and calendar years.

Results: This study included 64 925 and 133 200 patients with prostate cancer in CPRD GOLD and Aurum, respectively, with a median age of 72 (65-78) years. The overall IR of prostate cancer was 151.7 (95% CI, 150.6 to 152.9) per 100 000 person-years in GOLD to 153.1 (95% CI, 152.3 to 153.9) per 100 000 person-years for Aurum and increased with age. The incidence of prostate cancer increased from 109 per 100 000 person-years in 2000 to 159 per 100 000 person-years in 2021. Peaks of incidence occurred in 2004 and 2018, before a decline in 2020. PP increased 3.5 times over the study period for both databases, from 0.4% in 2000 to 1.4% in 2021. IR and PP were highest in those aged 80 to 89 years. Median (95% CI) survival was similar in both databases (GOLD: 10.9 [95% CI, 10.7-11.1] years and Aurum: 11.1 [95% CI, 11.0-11.2] years). Survival at 1, 5, and 10 years after diagnosis were 93.4% (95% CI, 93.2%-93.6%), 71.8% (95% CI, 71.4%-72.2%), 53.2% (95% CI, 52.6%-53.7%) in GOLD and 93.9% (95% CI, 93.7%-94.0%), 72.7% (95% CI, 72.5%-73.0%), 53.7% (95% CI, 53.3%-54.1%) in AURUM, respectively. Survival increased over time: 1-year survival was 94.8% (95% CI, 94.5%-95.2%) in those diagnosed between 2015 to 2019 compared with 90.8% (95% CI, 90.2%-91.3%) from 2000 to 2004; 5-year survival improved from 65.3% (95% CI, 64.4%-66.3%) from 2000 to 2004 to 75.3% (95% CI, 74.4%-76.3%) in 2015 to 2019.

Conclusions and relevance: In this population-based cohort study, incidence and prevalence increased with older age, with high survival rates reflecting a high burden of disease, particularly in the management of cancer survivorship in an aging population. Health care systems should consider this when managing the increasing numbers of people with prevalent prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Barclay reported receiving personal fees from Roche Consultancy and being the managing director of Sleep Universal Limited outside the submitted work. Dr Prieto-Alhambra reported receiving grants from European Medicines Agency, Innovative Medicines Initiative, Amgen, Chiesi, and UCB Biopharma and personal fees from Astellas, Amgen, Astra Zeneca, and UCB Biopharma outside the submitted work.

Figures

Figure 1.
Figure 1.. Annualized Incidence Rates of Prostate Cancer Stratified by Database
Shaded areas represent 95% CIs. CPRD indicates Clinical Practice Research Datalink.
Figure 2.
Figure 2.. Annualized Incidence Rates of Prostate Cancer Stratified by Database and Age Group
Shaded areas represent 95% CIs. There were not enough data points in those aged 18 to 39 years old to assess annualized trends across the study period. CPRD indicates Clinical Practice Research Datalink.
Figure 3.
Figure 3.. Annualized Period Prevalence of Prostate Cancer Stratified by Database and Age Group
Shaded areas represent 95% CIs. There were not enough data points in those aged 18 to 39 years to assess annualized trends. CPRD indicates Clinical Practice Research Datalink.
Figure 4.
Figure 4.. Kaplan-Meier Survival Curve of Prostate Cancer Stratified by Database
Shaded areas represent 95% CIs. CPRD indicates Clinical Practice Research Datalink.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660 - DOI - PubMed
    1. NICE Clinical Knowledge Summaries. What should I advise about screening for prostate cancer? National Institute for Health Care Excellence. Accessed August 13, 2024. https://cks.nice.org.uk/topics/prostate-cancer/diagnosis/screening-for-p...
    1. Prostate cancer risk management programme: overview. Public Health England. Accessed August 13, 2024. https://www.gov.uk/guidance/prostate-cancer-risk-management-programme-ov...
    1. Parker C, Castro E, Fizazi K, et al. ; ESMO Guidelines Committee . Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011 - DOI - PubMed
    1. NHS England. Checks for prostate cancer hit all-time high on back of NHS and charity awareness campaign. National Health Service. Accessed January 4, 2024. https://www.england.nhs.uk/2022/05/checks-for-prostate-cancer-hit-all-ti...

Publication types